

## Anti-Human Cytokeratin 19 Purified

**Catalog Number:** 14-9898

**Also known as:** CK19, Keratin 19

**RUO: For Research Use Only. Not for use in diagnostic procedures.**

### Product Information

**Contents:** Anti-Human Cytokeratin 19  
Purified



**Catalog Number:** 14-9898

**Clone:** BA17

**Concentration:** 0.5 mg/mL

**Host/Isotype:** Mouse IgG1, kappa



**LOT**



**Formulation:** aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer  
**Temperature Limitation:** Store at 2-8°C.

**Batch Code:** Refer to vial

**Use By:** Refer to vial

**Contains sodium azide**

### Description

This BA17 monoclonal antibody reacts with human cytokeratin 19 (CK19), a 44-kDa type I (acidic) intermediate filament protein that lacks the non-alpha-helical tail domain present in other keratins. Cytokeratins form the intracellular cytoskeletal network that maintains the integrity and stability of cells and tissues. Cytokeratin 19 is expressed in a wide variety of simple and stratified epithelial tissue. Moreover, cytokeratin 19 expression can be induced by vitamin A, SV40 transformation, and cancer. A soluble form of cytokeratin 19 generated by caspase 3 cleavage has also been found to be secreted by cancer cells, thus possibly indicating tumor metastasis. Cytokeratin 19 often exists as a heterodimer with cytokeratin 7, a type II keratin.

### Applications Reported

This BA17 antibody has been reported for use in immunohistochemical staining of formalin-fixed paraffin embedded tissue sections and immunocytochemistry.

### Applications Tested

This BA17 antibody has been tested by immunocytochemistry of fixed and permeabilized MCF-7 cells. This can be used at less than or equal to 10 ug/mL. It is recommended that the antibody be titrated for optimal performance in the assay of interest.

### References

Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. *Breast Cancer Res.* 2009;11(3):R39.

Moll R, Divo M, Langbein L. The human keratins: biology and pathology. *Histochem Cell Biol.* 2008 Jun;129(6):705-33.

Bártek J, Bárteková J, Taylor-Papadimitriou J, Rejthar A, Kovarik J, Lukás Z, Vojtesek B. Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. *Histochem J.* 1986 Oct;18(10):565-75. (**BA17**, IHC)

Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. *EMBO J.* 1986 Aug;5(8):1865-75.

### Related Products

14-4714 Mouse IgG1 K Isotype Control Purified (P3.6.2.8.1)

Not for further distribution without written consent.

Copyright © 2000-2012 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • [www.ebioscience.com](http://www.ebioscience.com) •  
[info@ebioscience.com](mailto:info@ebioscience.com)